Oclaro and Opnext Announce Successful Merger Execution

Oclaro, a tier-one supplier of optical communications and laser solutions, and Opnext, a company specializing in optical modules, subsystems, and components, declared that their merger, which came to an end on July 23, 2012, has achieved shareholder approval.

The integrated company will function under the Oclaro name. It recently launched brand identity and a new logo to mark the establishment of a new operating company within the optical industry.

At present, Oclaro is considered as the second largest supplier of optical components, subsystems and modules to the markets of industrial and consumer laser and optical communications. Having 3,200 employees operating globally, Oclaro represents combined revenues of $833 M for the fiscal year completed July 2, 2011. The company has over 30 years of integrated expertise in optical technology innovation from companies including Opnext, Corning, Hitachi, Nortel, Marconi, Avanex, Alcatel, and Bookham.

The extensive product portfolio of Oclaro encompasses modules, subsystems, and components capable of receiving, transmitting, and amplifying light signals over fiber optic networks that result in new series of high speed services in the core optical network, and data center markets. Oclaro’s laser diode solutions supply the power required for illumination, marking, heating, cutting, and welding for an extensive range of new applications within the consumer electronics, medical and industrial markets.

A new board of directors and management team was selected for the newly-established combined company. The Chairman and CEO- Alain Couder, and Opnext Chairman and CEO Harry Bosco joined the board of directors. Independent directors within the board includes Greg Dougherty (director), Joel A. Smith III (lead independent director), and Lori Holland, Edward Collins, Marissa Peterson, Bill Smith, Kendall Cowan, and Dr. David Lee as directors.

Afixed ratio of 0.42 shares of Oclaro common stock will be given to Opnext shareholders for every share of their proprietary Opnext common stock.

Disclaimer: The views expressed here are those of the author expressed in their private capacity and do not necessarily represent the views of AZoM.com Limited T/A AZoNetwork the owner and operator of this website. This disclaimer forms part of the Terms and conditions of use of this website.

G.P. Thomas

Written by

G.P. Thomas

Gary graduated from the University of Manchester with a first-class honours degree in Geochemistry and a Masters in Earth Sciences. After working in the Australian mining industry, Gary decided to hang up his geology boots and turn his hand to writing. When he isn't developing topical and informative content, Gary can usually be found playing his beloved guitar, or watching Aston Villa FC snatch defeat from the jaws of victory.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Thomas, G.P.. (2022, July 18). Oclaro and Opnext Announce Successful Merger Execution. AZoOptics. Retrieved on November 23, 2024 from https://www.azooptics.com/News.aspx?newsID=15903.

  • MLA

    Thomas, G.P.. "Oclaro and Opnext Announce Successful Merger Execution". AZoOptics. 23 November 2024. <https://www.azooptics.com/News.aspx?newsID=15903>.

  • Chicago

    Thomas, G.P.. "Oclaro and Opnext Announce Successful Merger Execution". AZoOptics. https://www.azooptics.com/News.aspx?newsID=15903. (accessed November 23, 2024).

  • Harvard

    Thomas, G.P.. 2022. Oclaro and Opnext Announce Successful Merger Execution. AZoOptics, viewed 23 November 2024, https://www.azooptics.com/News.aspx?newsID=15903.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.